Tubular aggregate myopathy (TAM) is a disorder characterized by slowly progressive muscle weakness and atrophy. The pathologic feature is the appearance of tubular aggregates in skeletal muscle. The tubular aggregates are a subsarcolemmal accumulation of granular materials that is stained bright purple with Gomori trichrome staining and exhibits accumulation of regular arrays of membrane tubules under an electron microscope.^[@R1]^ The tubular aggregates are thought to originate from sarcoplasmic reticulum (SR)^[@R2]^; however, the exact mechanism leading to their formation and the significance on muscle fibers remain unknown.^[@R3]^

Recently, several mutations in stromal interaction molecule 1 (*STIM1*), a Ca^2+^ sensor in SR, have been identified in dominantly inherited TAM (OMIM \#160565).^[@R4][@R5][@R6]^ All mutations demonstrated so far have been missense mutations located in the EF hand of the N-terminal luminal region and are thought to disrupt the Ca^2+^ binding to this region. In this article, we present a dominant TAM family in whom a novel insertion mutation was identified in the C-terminal inhibitory domain (CTID) located in the cytoplasmic region of *STIM1* and investigate the functional significance of the mutation using cultured cells.

METHODS {#s1}
=======

Standard protocol approvals, registrations, and patient consents. {#s1-1}
-----------------------------------------------------------------

This study was approved by the institutional review board of Teikyo University. The patients gave written informed consent to participate in this study.

Histologic analyses. {#s1-2}
--------------------

Muscle specimens were taken from the biceps brachii muscle. Standard techniques were used for the preparation of frozen sections; hematoxylin and eosin (H&E), Gomori trichrome, NADH-tetrazolium reductase (TR), and ATPase staining; and immunofluorescent and electron microscopic analysis. Mouse monoclonal antibody against STIM1 and rabbit polyclonal antibody against ORAI were obtained from BD Biosciences (Franklin Lakes, NJ) and Merck (Darmstadt, Germany), respectively.

Genetic analysis. {#s1-3}
-----------------

Genomic DNA samples were extracted from peripheral blood leukocytes. Exonic sequences were enriched using a SureSelect v5+UTRs kit (Agilent, Santa Clara, CA) and subjected to nucleotide sequence analysis using a Hiseq2500 platform (Illumina, San Diego, CA). Burrows-Wheeler Aligner and Samtools were used with default settings for the alignment of raw reads and variant detection. The protein-altering variants in *STIM1* and *ORAI1* were filtered by excluding those present in 600 healthy Japanese controls. Direct nucleotide sequence analysis was performed using an ABI 3100 Genetic Analyzer (Thermo Fisher Scientific, Waltham, MA). Messenger RNA (mRNA) was extracted from muscle biopsy specimen using RNeasy Fibrous tissue mini kit (Qiagen, Hilden, Germany) and amplified by reverse transcriptase (RT)-PCR with SuperScript (Thermo Fisher Scientific).

Expression study of *STIM1* in C2C12 myoblasts. {#s1-4}
-----------------------------------------------

Expression plasmid encoding human *STIM1* complementary DNA was purchased from OriGene and the mutation c.1450_1451insGA was introduced with a KOD-Plus mutagenesis kit (Toyobo, Osaka, Japan). Two days after transfection using Effectene (Qiagen), C2C12 myoblasts were labeled with anti-*STIM1*, Alexa Fluor 594--conjugated phalloidin (Thermo Fisher Scientific) and 4′,6-diamidino-2-phenylindole (DAPI). The images were obtained using an FSX100 fluorescence microscope (Olympus, Tokyo, Japan). Statistical differences were evaluated by the *t* test.

Measurement of changes in intracellular Ca^2+^ concentration. {#s1-5}
-------------------------------------------------------------

Ca^2+^ measurements were carried out as previously described^[@R7]^ with minor modifications. HEK293 cells were cotransfected with plasmids expressing *STIM1* and pIRES2-mCherry. Transfection was carried out using X-tremeGENE HP transfection reagent (Roche, Basel, Switzerland). Transfected HEK293 cells were trypsinized and seeded onto poly-[l]{.smallcaps}-lysine--coated glass coverslips the next day. Ca^2+^ imaging was performed 42--48 hours after transfection. HEK293 cells on coverslips were loaded with Fura-2 by incubation in Dulbecco\'s modified Eagle medium containing 5 μM Fura-2/AM (Dojindo, Kumamoto, Japan) at 37°C for 40 minutes. The coverslips were then placed in a perfusion chamber mounted on the stage of a microscope (Axio-observer Z1; Carl Zeiss, Oberkochen, Germany). Transfected cells were identified by the detection of fluorescence from mCherry. Fura-2 fluorescence images recorded at 10-second intervals were analyzed using Physiology software (Carl Zeiss).

RESULTS {#s2}
=======

Clinical data. {#s2-1}
--------------

A 42-year-old Japanese man presented with difficulty walking. He first noticed slight difficulty walking when he was 37 years old. At the age of 40, running and climbing stairs became difficult. His mother also had difficulty walking and was in a wheelchair when she was 40 years old. His parents were not consanguineous. On neurologic examination, pupils and ocular movement were normal. The temporalis and masseter muscles on both sides were atrophic. Muscle atrophy and weakness was evident in all 4 limbs, and the bilateral triceps surae muscles were most prominently affected ([figure 1A](#F1){ref-type="fig"}). The paraspinal muscles were also atrophic and he had winged scapulae ([figure 1B](#F1){ref-type="fig"}). His gait was lordotic. Ankle joint contracture was observed bilaterally. He did not exhibit myalgia, cramps, scoliosis, rigid spine, or symptoms suggesting Stormorken syndrome, including miosis, thrombocytopenia, asplenia, or ichthyosis.^[@R8]^ He had no history of repetitive infections indicative of immunodeficiency.^[@R9]^ Blood cell counts and routine blood biochemistry were normal, except serum creatine kinase was elevated to 798 IU/L (normal range \<150). Needle EMG showed chronic myopathic changes. Muscle MRI revealed disseminated high-intensity areas on T1-weighted images in the quadriceps femoris, triceps surae, and paraspinal muscles, indicating fatty replacement in these muscles ([figure 1C](#F1){ref-type="fig"}).

![Clinical and pathologic findings in a patient with tubular aggregate myopathy\
(A) Muscle atrophy is evident in all 4 limbs. Among them, the triceps surae muscle (white arrowhead) is most prominently affected. (B) The patient exhibits winged scapulae due to atrophy of the paraspinal muscles. (C) Muscle MRI shows high-intensity areas on T1-weighted images in the quadriceps femoris, triceps surae, and paraspinal muscles, indicating fatty replacement in these muscles. (D) Hematoxylin and eosin (H&E) staining reveals the increased variability of muscle fiber diameter and occasional centrally nucleated fibers. Many fibers show tubular aggregates that are stained dark red by H&E (D), intense blue by NADH-tetrazolium reductase (E), and bright purple with Gomori trichrome staining (F). (G) A serial section stained with ATPase (pH 4.6) demonstrates that tubular aggregates are in type 2 fibers. Bar = 50 μm. (H) Electron microscopy shows that some areas in the myofiber are replaced by numerous tubular structures. At higher magnification, each tubule is arranged in a honeycomb-like structure showing double-walled membranes (inset). Bar = 1 μm. PS = paraspinal muscles; QF = quadriceps femoris; TS = triceps surae.](NG2015000034FF1){#F1}

Pathologic findings. {#s2-2}
--------------------

H&E staining demonstrated increased variability of muscle fiber diameter and occasional centrally nucleated myofibers. In addition, many fibers showed irregularly shaped dark red staining ([figure 1D](#F1){ref-type="fig"}). These dark red accumulations were stained intense blue by NADH-TR ([figure 1E](#F1){ref-type="fig"}) and bright purple with Gomori trichrome staining ([figure 1F](#F1){ref-type="fig"}), indicating that these are tubular aggregates. A serial section stained with ATPase (pH 4.6) further demonstrated that the tubular aggregates were in type 2 fibers ([figure 1G](#F1){ref-type="fig"}). Electron microscopic analysis revealed that some areas in the myofiber were replaced by numerous tubular structures ([figure 1H](#F1){ref-type="fig"}) and that each tubule was arranged in a honeycomb-like structure that showed double-walled membranes at higher magnification ([figure 1H](#F1){ref-type="fig"}, inset).

Genetic analysis and localization of *STIM1* in skeletal muscle. {#s2-3}
----------------------------------------------------------------

The clinical and microscopic findings characteristic of TAM prompted us to perform genetic analysis. Exome sequence analysis and subsequent Sanger sequencing of the proband revealed a novel heterozygous insertion mutation, c.1450_1451insGA (p.Ile484ArgfsX21), in exon 7 of *STIM1* ([figure 2A](#F2){ref-type="fig"}). The same mutation was identified in his mother but not in healthy family members ([figure 2B](#F2){ref-type="fig"}). The amino acid 484 resides in the CTID located in the cytoplasmic region of *STIM1* ([figure 2C](#F2){ref-type="fig"}). To assess the localization of STIM1 in the skeletal muscle of the patient, we performed immunofluorescent microscopic analysis. The immunolabeling of STIM1 and ORAI1, a calcium channel in plasma membrane, colocalized to the tubular aggregates visualized by Gomori trichrome staining ([figure 2D](#F2){ref-type="fig"}), which is consistent with previous reports.^[@R4],[@R7]^ Because premature termination codons often result in nonsense-mediated decay of mRNA, we analyzed mRNA transcript in the muscle biopsy specimen. Sequencing of the RT-PCR product demonstrated that both wild-type and the c.1450_1451insGA mutant transcripts are present ([figure 2E](#F2){ref-type="fig"}).

![Genetic analysis and expression of STIM1 in the skeletal muscle of a patient with tubular aggregate myopathy\
(A) Sanger sequencing reveals a heterozygous insertion mutation, c.1450_1451insGA, in *STIM1*. (B) Pedigree of the family indicates dominant inheritance and sequence analysis demonstrates the segregation of the heterozygous mutations with the disease. (C) Schematic representation of the domain structure of STIM1. The mutation p.Ile484ArgfsX21 resides in the C-terminal inhibitory domain (CTID), which is located in the cytoplasmic region of STIM1 (red type). All missense mutations reported so far reside in the EF hand in the luminal region (blue type). (D) Serial sections of Gomori trichrome staining and immunofluorescent images indicate that both STIM1 and ORAI1 colocalize to the tubular aggregates. Bar = 50 μm. (E) Sanger sequencing of reverse transcriptase-PCR product amplified from muscle biopsy specimen demonstrates that both wild-type and mutant transcripts are present. CC1 = coiled-coil region 1; K = polylysine; S = signal peptide; SAM = sterile α motif; SORE = STIM1 Orai activating region; SP = serine- and proline-rich domain; TM = transmembrane domain.](NG2015000034FF2){#F2}

Expression of mutant STIM1 in C2C12 myoblasts. {#s2-4}
----------------------------------------------

To investigate the functional significance of the c.1450_1451insGA mutation, we transfected C2C12 myoblasts with wild-type and mutant *STIM1*. Typically, wild-type STIM1 displayed diffuse distribution in C2C12 cells ([figure 3A](#F3){ref-type="fig"}). In sharp contrast, mutant STIM1 concentrated intensely around nuclei and exhibited an aggregation-like appearance in shrunk cytoplasm ([figure 3A](#F3){ref-type="fig"}). Counting cells with the diffuse vs aggregation-like localization of STIM1 confirmed that the majority of cells expressing wild-type STIM1 showed diffuse localization whereas most cells expressing mutant STIM1 exhibited an aggregation-like pattern ([figure 3B](#F3){ref-type="fig"}).

![Expression of mutant STIM1 in cultured cells and its effect on store-operated Ca^2+^ influx\
(A) C2C12 myoblasts were transfected with wild-type (WT) and the C-terminal inhibitory domain mutant *STIM1* and labeled with anti-*STIM1* antibody, phalloidin, and 4\',6-diamidino-2-phenylindole (DAPI). WT STIM1 displays diffuse distribution in C2C12 cells, whereas the signal of the mutant STIM1 concentrates intensely around nuclei and exhibits an aggregation-like appearance in the shrunk cytoplasm. Bar = 50 μm. (B) Seven stitching images (5 × 5) of the C2C12 myoblasts were captured using a fluorescence microscope, and the number of cells with diffuse vs aggregation-like localization of STIM1 was counted. The majority of cells expressing WT *STIM1* show diffuse localization, whereas most cells expressing the mutant STIM1 exhibit the aggregation-like pattern. (C) Intracellular Ca^2+^ concentration was measured in HEK293 cells expressing WT STIM1 (gray square; n = 40 cells), the mutant STIM1 (black triangle; n = 42 cells), or control (open circle; n = 47 cells). The perfusion solution was changed from HEPES-buffered saline (HBS) containing 2 mM Ca^2+^ to Ca^2+^-free solution containing 0.5 mM ethylene glycol tetraacetic acid (EGTA). To evaluate Ca^2+^ influx across the plasma membrane, 2 mM Ca^2+^ was applied to the cells. The duration of exposure to Ca^2+^-containing HBS and Ca^2+^-free HBS is indicated above the graph. (D) Maximal intracellular Ca^2+^ rises after readdition of 2 mM Ca^2+^ to the cells. Data points are mean ± SEM. *p* = 0.0028, 0.0104, and 0.5299 for WT vs mutant, control vs WT, and control vs mutant, respectively.](NG2015000034FF3){#F3}

Effects of *STIM1* mutation on store-operated Ca^2+^ entry--mediated Ca^2+^ influx. {#s2-5}
-----------------------------------------------------------------------------------

Finally, we performed Ca^2+^ measurements to examine whether the *STIM1* mutation affects store-operated Ca^2+^ entry (SOCE). The wild-type or the mutant STIM1 was expressed in HEK293 cells, and changes in the intracellular Ca^2+^ concentration (\[Ca^2+^\]~i~) were evaluated. As shown in [figure 3C](#F3){ref-type="fig"}, overexpression of wild-type STIM1 caused an increased \[Ca^2+^\]~i~ in the perfusion solution containing 2 mM Ca^2+^, suggesting that wild-type STIM1 enhanced Ca^2+^ influx through ORAI1 endogenously expressed in HEK293 cells. This notion was further confirmed by the fact that removal of the external Ca^2+^ by ethylene glycol tetraacetic acid led to decreased \[Ca^2+^\]~i~ and that readdition of Ca^2+^ to the perfusion solution resumed the Ca^2+^ response. However, the mutant STIM1-expressed cells did not show significant Ca^2+^ responses by the changes in the external Ca^2+^ concentration ([figure 3, C and D](#F3){ref-type="fig"}). These results collectively suggest that the *STIM1* mutation we found in this study causes dysregulated Ca^2+^ homeostasis.

DISCUSSION {#s3}
==========

In the present study, we described a family with dominant TAM with a novel frameshift mutation in the CTID of *STIM1*. Of note, the triceps surae muscles were most severely involved in our patient. This is in contrast to the previous reports of TAM, in which the proximal muscles were predominantly affected.^[@R4],[@R5]^ In skeletal muscle, Ca^2+^ homeostasis is regulated by SOCE. In SOCE, *STIM1* forms an oligomer upon the depletion of Ca^2+^ in SR and activates ORAI1 channels at sarcolemma, triggering extracellular Ca^2+^ entry.^[@R10]^ All *STIM1* mutations in TAM reported so far are missense mutations residing in the EF hand (EF1 and EF2 in [figure 2B](#F2){ref-type="fig"}), and this region is considered a hotspot.^[@R4][@R5][@R6]^ These mutations are presumed to induce the constitutive activation of ORAI1 and cause excessive Ca^2+^ influx into muscle cells.

In contrast, a frameshift mutation, which creates a premature stop codon in the CTID located in the C-terminal cytoplasmic region of *STIM1*, was identified in our family ([figure 2B](#F2){ref-type="fig"}). The CTID is known to interact with SOCE-associated regulatory factor (SARAF), a regulator of slow Ca^2+^-dependent inactivation of ORAI1.^[@R11]^ Following the transfection of C2C12 myoblasts with the CTID mutant *STIM1*, aggregation-like signals of STIM1 were observed around the nuclei. The aggregation-like appearance is distinct from that in C2C12 myoblasts transfected with *STIM1* harboring EF hand mutations, which exhibit numerous puncta-like small clusters in cytoplasm.^[@R4],[@R6]^

Furthermore, intracellular Ca^2+^ measurements revealed that the Ca^2+^ influx is significantly decreased in the cells transfected with the CTID mutant compared to the wild-type *STIM1*-transfected cells. This result is in marked contrast to the previous reports, in which increased Ca^2+^ influx caused by constitutive activation of SOCE was observed.^[@R4],[@R7]^ The transcript of CTID mutant was present in the affected skeletal muscle of our patient, suggesting that nonsense-mediated mRNA decay is not induced. We speculate that the CTID mutant may inhibit the oligomer formation of STIM1 necessary to activate the ORAI1 channels, leading to the decreased intracellular Ca^2+^ influx. Alternatively, the STIM1 oligomer including the CTID mutant may not translocate properly to the subsarcolemma where the oligomer interacts with ORAI1, because the CTID mutant lacks the polybasic motif (K in [figure 2C](#F2){ref-type="fig"}) necessary for the STIM1 targeting to plasma membrane.^[@R12]^ It is of particular interest to note that STIM2β, an alternatively spliced form of STIM2, converts STIM isoforms from an activator to an inhibitor of ORAI1.^[@R13]^ Our findings provide further evidence that the dysregulation of Ca^2+^ homeostasis underlies the pathomechanism of TAM.
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